Kexing Biopharm Co.,Ltd. (688136.SH) has announced that it recently received a Notice of Acceptance from the National Medical Products Administration regarding the marketing authorization application for its investigational drug, pegylated human granulocyte colony-stimulating factor injection (referred to as "GB-K02").
GB-K02 is intended for use in patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is prone to causing clinically significant febrile neutropenia, in order to reduce the incidence of infections manifested as febrile neutropenia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.